News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF L.A. McKeown March 06, 2023
News Conference News ACC 2023 COAPT at 5 Years: MitraClip Still Ahead, but Deaths and Crossovers Cast Shadows Shelley Wood March 05, 2023
News Conference News ACC 2023 Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies Caitlin E. Cox February 23, 2023
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020